THE PROBLEM
Malfunction of the lower esophageal sphincter results in acid reflux into the esophagus. Reflux is mostly episodic so that the esophagus is not often presented with a continuous acid load. Prediction of esophageal disease related to reflux takes into account the pH of the refluxate and the duration of reflux. Expulsion of the refluxate back into the stomach shortens the time of exposure. The volume of reflux is also an important parameter for estimation of the acid load on the esophageal epithelium. It is the magnitude of this acid load that determines the presence or absence of pathology or symptoms. Intraesophageal pH monitoring provides an approximate measure of the acid load to the lower esophagus [2, 3] The human esophageal epithelium is a multi-layered, stratified squamous epithelium. Afferent nerves are present, reaching into the superficial layers of the mucosa. With incompetence of the lower esophageal sphincter (LES)b, acid reflux results with pain and damage to the epithelium depending on the pH of the refluxate. Rather than being protected by a continuous tight junction, this epithelium has largely regional cell-to-cell contact via desmosomes but, being multi-layered, provides a winding path for proton diffusion into the epithelium. It is nevertheless significantly more acid sensitive than the gastric epithelium that is provided with "tight" tight junctions. [4] ) and perhaps also to reversal of the disulfide bond linking PPI to the pump. On once-a-day treatment, the inhibition of maximal acid output is about 70 percent [5] . Steady-state inhibition is found on about the third day on once-a-day treat-ment dosing since previously resting pumps have to be recruited to respond to the drug. Improvement in effect of PPIs is achieved by divided doses, not by increasing the single dose. On twice-a-day treatment, inhibition of maximal acid output rises to 80 percent and steady-state is achieved on day two.
Meta-analysis of the degree of acid inhibition required for optimization of healing rates for erosive esophagitis that has shown that elevation of mean diurnal intra-gastric pH to at least 4.0 is required for about 18 hr per day [6] . This result may reflect the calculated ability of the epithelium and its cells to handle acid reflux. This seems to be achieved in most patients on once-a-day PPI therapy. If eradication of Helicobacter pylori blunts the effect of PPIs on intragastric acidity, as has recently been suggested [7] , twice-a-day PPI therapy may be required to reach optimal healing pH.
Thus, inhibition to pH below 4.0 is sufficient to optimize healing but is often inadequate for complete symptom control, since intra-gastric acidity may increase to pH below 2.0, especially towards the end of digestion of a meal. Short periods of high acidity, which may not result in epithelial damage, may be sufficient to stimulate esophageal nerves, and the metaanalysis only addresses diurnal pH, not periods of high acidity.
Rapid symptom control may require more frequent dosing for the first three days until steady-state inhibition is reached or reformulation of the PPIs.
